Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
07/05/2024 17:30
* Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected
to show
a rise in quarterly revenue when it reports results on May 9
for the period ending March 31 2024
* The Cambridge Massachusetts-based company is expected to
report
a 8.9% increase in revenue to $8.5 million from $7.8 million a
year ago, according to the mean estimate from 8 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Mersana Therapeutics Inc
is
for a loss of 18 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 22.6%
in the last three months.
* Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $7.00, above its last closing price
of $3.50.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.12 -0.16 -0.16 Met 2.6
Sep. 30 2023 -0.35 -0.36 -0.27 Beat 25.4
Jun. 30 2023 -0.37 -0.44 -0.47 Missed -6.5
Mar. 31 2023 -0.40 -0.44 -0.52 Missed -19.3
Dec. -0.47 -0.50 -0.44 Beat 12.8
31 2022
Sep. 30 2022 0.04 -0.09 -0.61 Missed -577.8
Jan. 1 0001 -0.53 -0.52 -0.55 Missed -5.8
Mar. 31 2022 -0.32 -0.32 -0.59 Missed -85.2
This summary was machine generated May 7 at 16:30 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)